GET DAILY SIGNALSPRFX Stock: Narrow Range Holds as PRF Technologies Shifts Focus Beyond Pain Pipeline
Key Takeaways
- PRFX has traded in a relatively narrow range over the last 30 days, edging about 0.8% lower from roughly $0.88 to $0.87 between early October and early November 2026.
- The trailing three-month picture is weaker, with shares down approximately 16% amid continued pressure on a low-float, pre-revenue micro-cap.
- Renamed PRF Technologies from PainReform in January 2026, the company now spans specialty pharmaceuticals, ophthalmic drug delivery, and AI-driven solar analytics.
- Legacy lead candidate PRF-110 missed its Phase 3 primary endpoint in late 2024, shifting strategic focus toward the OcuRing-K and DeepSolar platforms.
- A 1-for-5 reverse stock split completed in February 2026 and an auditor going-concern note underline the company's liquidity and capital-structure risks.
- For deeper detail, review PRFX Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading strategies approach active tickers.
Current Market Snapshot
PRFX is a low-priced, pre-revenue micro-cap that has exhibited elevated volatility and relatively thin trading. Over the last 30 days, the stock has largely held within a modest range, moving from about $0.88 in early October to roughly $0.87 by early November 2026 — a decline of less than 1% — despite intermittent intraday swings and occasional volume spikes. This stability stands in contrast to a steeper drawdown over the prior quarter, reflecting both the stock's small float and investors' wait-and-see posture as the company works to fund and advance a diversified platform. Broader sentiment remains shaped by clinical-stage execution risk, limited cash, and the company's pivot beyond its original single-asset focus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
PRF Technologies Business Overview and Competitive Position
PRF Technologies, formerly PainReform Ltd., is a diversified innovation company headquartered in Tel Aviv, Israel. Its pharmaceutical heritage centers on PRF-110, an oil-based, viscous extended-release formulation of the local anesthetic ropivacaine designed for localized post-operative pain relief. After PRF-110 failed to meet its primary endpoint in a Phase 3 bunionectomy trial in late 2024, the company broadened its strategy.
Through a majority stake in LayerBio, PRF is advancing OcuRing-K, a patented, sustained-release, dropless ocular therapy targeting pain and inflammation after cataract surgery. In parallel, its DeepSolar platform applies AI-driven analytics to utility-scale solar assets, with offerings including technical due diligence and AI-based production forecasting developed within NVIDIA's Connect Program. This multi-platform structure reduces reliance on any single program but also leaves the company dependent on external financing, since it has not yet generated significant revenue.
Recent Developments Driving PRFX
The last 30 days have been comparatively quiet on company-specific news, with price action reflecting micro-cap liquidity and sentiment more than a single catalyst. The shares traded within a range of roughly $0.70 to $0.88, punctuated by an unusually volatile session in early November that saw intraday movement across a wide span alongside a sharp volume increase.
Structurally, several recent items continue to frame how investors view PRFX. The corporate name change to PRF Technologies in January 2026 signaled a deliberate shift beyond its original pain-focused pipeline. The February 2026 1-for-5 reverse stock split was intended to support Nasdaq listing compliance, while the auditor's going-concern qualification and a cash balance of about $3.2 million at the end of 2025 highlight the need for additional capital. On the clinical front, a May 2026 announcement that PRF-110 demonstrated sustained 72-hour analgesic activity in a head-to-head preclinical study provided a scientific update, though it did not alter the fact that the asset is no longer the company's primary clinical focus.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors are likely to shape PRFX. The most important near-term question is funding: with an auditor's going-concern warning and limited cash, the company's ability to raise equity or secure strategic partnerships will influence its capacity to advance its programs. On the pharmaceutical side, progress for OcuRing-K toward the next stage of clinical development represents the clearest pipeline catalyst. In energy, DeepSolar's transition from pilots into commercial customer engagements and revenue generation will be closely watched.
Investors should also monitor regulatory and listing-compliance developments, any updated guidance on PRF-110, and broader sector sentiment toward speculative, pre-revenue healthcare and clean-energy names. Because the company has yet to generate meaningful revenue, execution milestones and capital events — rather than traditional earnings fundamentals — are likely to remain the dominant drivers of the stock.
Using Tickeron AI Trading Bots for Context
In my own work, I often review Tickeron’s AI Trading Bots to compare automated strategies across volatile names like this one. The platform surfaces hundreds of bots with different holding periods and performance metrics, which helps add a layer of quantitative perspective alongside fundamental review without replacing traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for PRFX turns positive, indicating new upward trend
PRFX saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned positive. In 89 of the 99 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRFX's RSI Oscillator exited the oversold zone, 46 of 52 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PRFX just turned positive on October 28, 2026. Looking at past instances where PRFX's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRFX advanced for three days, in 154 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRFX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PRFX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRFX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.192) is normal, around the industry mean (7.271). P/E Ratio (-0.213) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (34.722) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PRFX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement